Olanzapine, quetiapine, or risperidone did not differ from placebo for Alzheimer disease

摘要

Psychosis, aggression, and agitation in AD are typically more disturbingnand challenging for physicians and caregivers than are memory lossnand other aspects of cognitive impairment that define the disease. Thenwell-done study by Schneider and colleagues, with a primary endpointnbeing time to discontinuation of the medication, closely resemblesnclinical practice.